Latest Breaking News On - Mike tattory - Page 7 : comparemela.com

EFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer

The Company’s eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk patients as well as high-risk patients carrying specific markers. | April 11, 2023

United statesDoug warnerChristopherm calabreseKevin gardnerChristina curtisJennifer caswell jinMike tattoryExchange commissionLifesci communicationsEffector therapeutics incAssistant professorStanford medicineBiomedical data scienceArtificial intelligenceCancer genomicsPrivate securities litigation reform act

QUANTUM GENOMICS: Quantum Genomics announces reorganization of its Board of Directors and staff restructuration in order to focus on new projects

Quantum Genomics announces reorganization of its Board of Directors and staff restructuration in order to focus on new projects Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical

New yorkUnited statesFrance generalDennis riedlJean philippe milonCatherine llorens cortMike tattoryDescartes universityQuantum genomicsEuronext growthQuantum genomic boardOtium capitalIndependent administratorCarole wassermannQuantum genomicParis descartes university

Ambrx Biopharma Strengthens Clinical Leadership with Appointment of Sandra Aung, Ph D as Head of Cl

SAN DIEGO (BUSINESS WIRE) Ambrx Biopharma, Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody-drug conjugates (ADCs), has appointed Sandra Aung, Ph.D., as Executive Vice President, Head of Clinical Developm.

Mike moyerSandra aungDaniel oconnorMike tattoryBiologics epbsNational cancer institute institutes of healthScripps research instituteCell genesys incAmbrx biopharma incHead of clinical developmentUbivac incLifesci communicationsSmall business innovate researchVanderbilt universityAmbrx biopharmaEngineered precision biologics

Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment

Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan antonioMike moyerSara hurvitzDaniel oconnorMike tattoryBiologics epbsExchange commissionLifesci communicationsAmbrx biopharma incProfessor at david geffen school of medicineWall streetSpotlight poster presentationAntonio breast cancer symposiumDrug conjugateEngineered precision biologics

QUANTUM GENOMICS: Quantum Genomics gives an update

Quantum Genomics gives an update Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medications that directly

New yorkUnited statesFrance generalCatherine llorens cortesMike tattoryFrance french national institute of healthScientific centre for national researchDescartes universityQuantum genomicsEuronext growthParis descartes universityFrench national instituteMedical researchScientific centreNational research